Abstract: Human lung cancer remains one of the deadliest diseases worldwide. New approaches are needed for improved lung cancer treatment. In this study, we found that M. tuberculosis culture supernatant (TB-SN) could inhibit human lung cancer cell proliferation through a caspase-dependent apoptosis pathway and induce cell cycle arrest in G1 phase. The active components responsible for the growth inhibitory activities were attributed to some proteins or protein complex with molecular weight more than 100 kD. These findings are significant and may provide new insight into a possible antagonism between M. tuberculosis and lung cancer and also have implications for development of an alternative approach for lung cancer treatment.
INTRODUCTION
Cancer remains one of the most dangerous human diseases despite significant progress in cancer research and treatment in the past several decades. In 2007, it is estimated that 1.4 million people were diagnosed with cancer in the United States with 559,650 deaths [1] . According to the SEER Cancer Statistics Review, men have a 45% lifetime risk of being diagnosed with any type of cancer and women have a 38% chance of being diagnosed with any type of cancer [1] . Cancer rates could increase by as much as 50 percent to 15 million new cases by 2020 in the world [2] . The predicted increase will be mainly attributable to increases in the age of populations, the prevalence of smoking, and unhealthy diets [3] . In the year 2000, malignant tumors were implicated in nearly 12 percent of all human deaths worldwide from all causes. In many countries, more than 25 percent of all deaths are related to cancer [4] . In particular, human lung cancer is the second most common cancer and is the deadliest cancer that is the top cancer killer for both men and women. Although it accounts for just 13% of cancer cases, lung cancer is responsible for nearly one-third of all cancer deaths in men (32%) and one-quarter of those in women (25%) [4, 5] .
Currently, chemotherapy is the main standard treatment for human tumors. Although chemotherapy significantly improves symptoms and the quality of life of patients with *Address correspondence to this author at the Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, 615 N. Wolfe Street, Baltimore, MD 21205, USA; Tel: 410-614-2975; Fax: 410-955-0105; E-mail: yzhang@jhsph.edu lung cancer, only modest increase in survival rate can be achieved [6] [7] [8] [9] . One of the major reasons is the significant side effects and toxicity of current chemotherapy drugs. Several new alternative therapeutic approaches have been tried in the past few years. Bacteria can be used in combination with bacteriolytic therapy (COBALT), i.e., bacteria are administered together with conventional chemotherapeutic drugs to treat tumors [3] . These therapies take advantage of the ability of some bacteria to grow under hypoxic conditions. It is known that most advanced tumors have areas of poorly vascularized compartments creating hypoxic conditions, which render the cancer cells relatively resistant to conventional chemotherapy and radiation. Vogelstein and colleagues employed anaerobic bacteria Clostridium novyi in COBALT and achieved promising results for the treatment of cancer in a mouse model [10] . They created a strain of C. novyi devoid of its lethal toxin (C. novyi-NT) and intravenously injected C. novyi-NT spores into the avascular regions of tumors in mice. Most surrounding viable tumor cells were destroyed. When administered together with conventional chemotherapeutic drugs, they found that extensive hemorrhagic necrosis of tumors was developed and could result in significant and prolonged antitumor effects [10] . They also combined these bacteria with traditional radiotherapy and found it could also markedly improve the efficacy of radiotherapy [11] . Some bacteria can also be used as a delivery vector to effectively target tumors, which can replicate within tumors and inhibit tumor growth [12] . This new technology is called TAPET (Tumor Amplified Protein Expression therapy), an investigational anti-cancer gene, or protein, delivery vector [12] . Currently, Salmonella bacteria are often chosen for this purpose because they can proliferate rapidly, be easily modified genetically, and grow under both aerobic and anaerobic conditions. These bacterial strains have been designed to be highly selective for tumor tissue, relative to normal tissue, and to expand within the confines of the tumor to levels hundreds and even thousands of times greater than in normal tissue [13] [14] .
Some bacteria have been found to have significant antitumor activities. It has been reported that Lactobacillus species had significant cytotoxic effects on human bladder cancer in vitro and in vivo [15] [16] [17] . Attenuated Salmonella could also produce tumor growth inhibition [18] . Among all the bacteria that have anti-tumor activities, mycobacteria could be one of the most promising ones. The idea that mycobacteria could be used to treat human cancer has a long history. The first mycobacterium reported to have anti-tumor activity was BCG (derived from M. bovis, a member of the M. tuberculosis complex) [19] , which is now widely used to treat human superficial bladder cancer [20, 21] . It is thought that BCG might regulate human immune function and stimulates T lymphocytes to secrete cytokines (such as tumor necrosis factors, TNF) or other factors, which then kill tumor cells through a non-specific stander-by mechanism [21] . However, it is interesting to note that BCG is only effective in treating superficial surface located bladder cancer but not non-surface located bladder cancer, suggesting that BCG may also have direct effect on cancer cells besides its immunostimulatory role. Saitoh and Morales did provide evidence that BCG and BCG components could induce cancer cell apoptosis and exert cytotoxic effects [22] . It was also reported that other mycobacteria, such as M. phlei, or mycobacterial components, such as mycobacterial cell wall and DNA have certain anti-tumor activity [23, 24] .
That mycobacteria could provide a promising way to treat human cancer, also receives support from occasional clinical observations. Some case reports about the relationship between M. tuberculosis and human cancer were published in the past few years [25, 26] . Interestingly, one report showed that a patient with lung cancer was completely recovered when he had tuberculosis [26] . It is likely that M. tuberculosis could exert a direct effect on cancer cells besides its stimulation of the immune system. M. tuberculosis is known to cause characteristic pathology of necrosis and liquefaction, which we may take advantage for lysing cancer cells. However, the real effects of M. tuberculosis on human lung cancer and its mechanism are still unclear and need further investigation. In this study, we found that TB culture supernatant (TB-SN) had growth inhibitory effect on various human cancer cells. In addition, we showed that TB-SN could significantly inhibit cancer cell proliferation and induce apoptosis and cell cycle arrest in lung cancer cell line A549. Finally, we demonstrated that the growth inhibitory activity of TB-SN was attributed to some proteins or protein complexes of high molecular weight.
MATERIALS AND METHODS

Cell Cultures
Human cancer cell lines A549, MCF7, SKBR3, AU565, HCC1937, Capan 1, BXPC3, ASPC1, HepG2 and AGS were obtained from ATCC (American Type Culture Collection). Cells were grown in DMEM medium (GIBCO) supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 ug/ml streptomycin at 37 o C in an incubator containing 5% CO 2 . Avirulent M. tuberculosis strain H37Ra was cultured in Sauton's medium. E. coli strain BL21 was cultured in M9 minimal medium.
Preparation of M. tuberculosis Culture Supernatant
M. tuberculosis strain H37Ra bacteria were inoculated into Sauton's medium and incubated at 37 o C without shaking for one month. Supernatants of the mycobacterial culture were collected and concentrated by Series 8000 Stirred Cells with Ultrafiltration Membranes (5000 NMWL) (Millipore). Protein concentration was determined by using BCA protein assay kit (Pierce, USA). TB cellular fractions, including cell wall (CW), whole cell lysate (WCL), culture filtrate proteins (CFP), were obtained from Mycobacteria Research Laboratories, Colorado State University.
Cell Growth Inhibition Assay
MTT (3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide Sigma) assay was used to evaluate the growth inhibitory activity of TB-SN on cancer cells. Briefly, cells were seeded at a concentration of 1.5 x 10 4 cells/ml in a 96-well plate. After overnight incubation, various concentrations of TB-SN as indicated were added and cells were incubated in a humidified atmosphere with 5% CO 2 for 3 days. Sauton's medium was used as a control and was found to have no growth inhibitory activity on cancer cells. Then, 20 l MTT solution (4.14 mg/ml) was added to each well and incubated at 37 o C for 4 hours. The medium was removed and the formazan was dissolved in DMSO and the optical density was measured at 590 nm using a Bio-assay reader (Bio-Rad, USA). The growth inhibition was calculated as:
Cytotoxicity Assay
The cytotoxic activity was assessed by detection of lactate dehydrogenase (LDH) release from dead cells after TB-SN treatment using Cytotoxicity Detection Kit (LDH) from Roche Applied Science following the manufacturer's protocol. Briefly, cell-free culture supernatants of TB-SN treated cancer cells were collected and transferred to microtiter plates. Then substrate mixture containing tetrazolium salts was added, and incubated for 3 h before the absorbance was measured at 490nm.
Apoptosis Assay
Vybrant
® Apoptosis Assay Kit # 3 (FITC Annexin V/propidium iodide) was used to determine the percentage of cells undergoing apoptosis after TB-SN treatment as described by the manufacturer. Apoptotic cells were visualized by fluorescence microscopy and expressed as a percentage of apoptotic cells. A control without staining was also prepared.
Microarray and Data Analysis
Human lung cancer cell line A549 cells were collected and washed with PBS after treatment with TB-SN for 3 days and then lysed with Lysing Matrix D (Qbiogen) and Trizol LS. Subsequently, RNA was extracted according to the InVitrogen Trizol LS protocol with minor modification. The RNA was then purified following Qiagen RNeasy Total RNA Cleanup Protocol and quantified and qualified using Beckman spectrophotometer and RNA Nano LabChip analysis separately. For each sample, 7.5 g RNA was reversed transcribed to obtain the cDNA strands by Superscript II reverse transcriptase (Life Technologies) using T7-(dT)24 primer containing a T7 RNA polymerase promoter. The cDNA generated was in vitro transcribed to generate complementary RNA (cRNA) using BioArray High Yield RNA Transcript Labeling Kit (ENZO) for microarray analysis.
GeneChip
® Human Genome Focus Array (Affymetrix, Santa Clara, CA), which represent 8793 verified human sequences from the NCBI RefSeq database, were used in the microarray experiment performed according to the manufacturer's protocol. For each sample, ten microgram of cRNA was hybridized to the array according to the protocol. The eukaryotic hybridization controls were used to assess hybridization quality and array performance. The synthetic control oligo B2 provided alignment signals used by the software to position a grid over the array image. Ratios of signal for probe sets at 5V and 3V regions of housekeeping genes were calculated and monitored as an indication of transcript quality for each sample. After hybridization, the array was washed, stained and scanned at emission wavelength of 570nm using a confocal scanner (Affymetrix, Santa Clara, CA). The image data from the probe array scan was created and stored as data files for data analysis commenced with Absolute and Comparison analyses performed with Microarray suite 5.0 software. A fold change calculation was also computed to indicate the relative change of each transcript represented on the probe array. Further analyses with Data Mining Tool (Affymetrix) and GeneSpring (Silicon Genetics) were also performed.
Cell Cycle Analysis
Flow cytometry was used to quantitatively detect the cell-cycle distribution of cancer cells treated with TB-SN. Cells were plated into 10-cm tissue culture dishes 1 day before treatment with TB-SN. After treatment with TB-SN (5 g/ml) for 3 days, cells were harvested, washed with PBS, fixed in 70% ethanol overnight at 20 °C for at least 12 h. After two washes with phosphate buffered saline (PBS), the cells were incubated in RNase A/PBS (100 g/ml) at 37 °C for 30 min and stained with 50 g/ml propidium iodide (PI) by incubation at 4 o C for 15 min. The stained cells (about 10 5 cells) were analyzed by MoFlo flow cytometer (Dako Cytomation, Fort Collins, CO).
Assessment of Caspase Activity
ApoAlert ® caspase fluorescent and colorimetric assays (BD Biosciences Clontech, CA, USA) were used to determine the activity of caspase-3, -8 and -9. After being incubated with TB-SN for 48 h, the cells were collected and lysed in ice-cold buffer. The homogenate was clarified by centrifugation at 12000 x g for 10 min at 4 °C. Caspase activities in the supernatant were determined by cleavage of the specific chromophore-conjugated substrates. The substrate peptides of caspase-3, -8 and -9 (DEVD, IETD and LEHD) were conjugated to 7-amino-4-trifluoromethyl coumarin (AFC), p-nitroaniline (p-NA) and 7-amino-4-methyl coumarin (AMC), respectively. The release of AFC and AMC (for caspase-3 and -9) was measured by quantifying fluorescent intensity in a fluorescence spectrophotometer (Hitachi F-2500, Japan). Caspase-8 activity was determined by absorbance of p-NA at 405 nm in a microplate reader
Semi-Quantitative RT-PCR Analysis
Semi-quantitative RT-PCR was carried out by using 50 ng of RNA extracted from both treated and untreated A549 cancer cells. SuperScript III Platinum SYBR Green One-Step qRT-PCR Kit (Invitrogen, Carlsbad, CA) was used. The confirmation experiments were preformed on an ABI Prism ® 7000 machine (Applied Biosystems, Foster City, CA). The reverse transcription was carried out at 55 °C for 20min, and the PCR reaction consisted of 40 cycles of denaturation (15 s at 95°C), annealing (30 s at 58 °C), and extension (30 s at 72°C). No-template reaction mixtures were included as negative controls. The primers used for STK6 were F (5´CCATGATGCTACCAGAGTCTAC CT3´) and R (5´GACAGGGCATTTGCCAATTCTG 3´), and for OR10H3 they were F (5´CGTGGCTGTGC CCATCTTGT 3´) and R (5´GGTGGATCACATTAGA CCCACAGA3´).
Statistical Analysis
One-way analysis of variance (ANOVA) was performed to determine the significance between groups. A p-value of less than 0.05 (p < 0.05) was considered as statistically significant.
RESULTS
Specific Growth Inhibitory Effect of TB-SN on Human Lung Cancer Cell Line A549
In order to determine the effects of M. tuberculosis on human cancer cells, the growth inhibitory effects of different components of M. tuberculosis on human lung cancer cell line A549 were tested, including cell wall (CW, 700 g/ml), whole cell lysate (WCL, 150 g/ml), culture filtrate proteins (CFP, 100 g/ml), live M. tuberculosis H37Ra (live TB, co-culture experiment), as well as M. tuberculosis culture supernatant (TB-SN, 5 g/ml). E. coli culture supernatant (E. coli-SN, 15 g/ml) was used as a control. As shown in Fig. (1A) , TB-SN had specific and high growth inhibitory effects on lung cancer A549 cells in a dose-dependent manner (Fig. 1B) . The IC50 of TB-SN on A549 cells was 5 g/ml. In contrast, the E. coli culture supernatant did not have significant anticancer activity.
To validate the effect of the growth inhibition effects, TB-SN was tested on 9 other cell lines including breast cancer cell lines MCF7, SKBR3, AU565, HCC1937, pancreatic cancer cell lines (Capan 1, BXPC3, ASPC1), liver (HepG2) and gastric (AGS) cancer cell lines. As shown in Fig. (2) , TB-SN at a concentration of 5 g/ml exhibited inhibitory effects on all the cancer cell lines tested, with growth inhibition rates ranging from 53% to 86%. Taken together, these data suggest that TB-SN have significant growth inhibitory effect on a variety of different cancer cell lines.
Cytotoxic Effects of TB-SN on A549 Cells
To determine the cytotoxic activity of TB-SN on A549 cells, the LDH cytotoxicity assay (Roche) was used. Untreated cells were used as negative control, and the cells treated with 1% Triton X-100 were used as positive control (100% LDH release). Cytotoxicity was expressed as percentage of positive control. Indeed, TB-SN showed significant cytotoxic effect on A549 cells. Treatment of TB-SN at concentration of 5 g/ml for 12 hours released 29.21% of total available LDH.
TB-SN Induced Apoptosis in a Caspase-Dependent Way
A549 treated with TB-SN showed apoptosis phenotype, as indicated by appearance of small nuclear bodies (data not shown). To provide evidence that apoptosis is the main mechanism for the inhibition by TB-SN on A549 cells, we performed TUNEL apoptosis assay as described in Methods. Indeed, TN-SN significantly induced A549 cell apoptosis. As shown in Fig. (3) , 36 .8% of TB-SN treated cells underwent apoptosis. In contrast, only 5.2% of cells underwent apoptosis in control group.
Apoptosis can be induced either by extrinsic pathway, which is mediated by Caspase 8, or by intrinsic pathway, which is mediated by Caspase 9. To further identify which apoptosis pathway was involved, Caspase 3/7, Caspase 8 and Caspase 9 were determined using Caspase-Glo ® Assays kit from Promega. As shown in Fig. (4) , caspase 3/7, 8 and 9 activities increased 6.61-, 4.72-and 1.98-fold separately after treatment with TB-SN for 48 hours at a concentration of 20 g/ml. If A549 cells were pre-treated with DEVD-fmk, a 
Microarray Analysis of TB-SN Induced Genes in Human Lung Cancer A549 Cells
To assess the expression profiles in the TB-SN treated cancer cells and better understand the mechanism of TB-SN induced cell apoptosis, Human Genome Focus Array (Affymetrix) chips were used in TB-SN treated A549 lung cancer cells for 4 hours and 5 days separately. Microarray results showed that TB-SN could dramatically change gene expression in A549 cells. After 4 hours TB-SN treatment, CCHCR1 was down-regulated nearly 200 fold, and RAB3A was up-regulated nearly 10 fold. After 5 days treatment with TB-SN, 7 genes were down-regulated and 8 genes were up-regulated over 10 fold as listed in Table 1 . It is interesting to note that four cell cycle related genes including GSPT1 [27] , CCND1 [28] , STK6 [29] UBE2V1 [30] , were dramatically down-regulated by more than 10 fold.
The first three of them are related to the G1/S transition of mitotic cell cycle. GSPT1 and STK6 are two G1/S transition regulation factors. Significant down-regulation of these two genes indicated that A549 cell cycle might be arrested at G1/S checkpoint. The down-regulation of CCND1 indirectly confirmed the assumption, as this gene expression is cell cycle regulated, low in G1/S and accumulated during G2/M. These data indicated that inducing cell cycle arrest could be another mechanism of the inhibitory effect of TB-SN on A549 cell proliferation. In addition, the gene expression profile also indicated that TB-SN treatment could affect cell signal transduction, especially the G-protein coupled receptor protein signaling pathway. At least four signal transduction related genes, including RAB3A, OR10H3, CALM1 [31] , and NTS, were drastically up-regulated or down-regulated. The first three were G-protein coupled receptor protein signaling pathway factors. To confirm the gene expression changes after TB-SN treatment demonstrated in microarray assay, STK6 and OR10H3 expression levels were detected using quantitative real-time PCR. As summarized in Table 2 , the qRT-PCR data was consistent with cDNA array data. 
Cell Cycle Analysis of TB-SN Treated Cancer Cells
To confirm that induction of cell cycle arrest is one of the mechanisms for inhibitory effect of TB-SN on A549 cell proliferation, flow cytometry cell cycle analysis was performed. A549 cells were first treated with TB-SN and then cell cycle was analyzed by using MoFlo Flow Cytometer. As expected, TB-SN induced cells arrest at G1/S checkpoints, with G1/S phase cell population increasing from 52.90% to 67.12% (Fig. 5) . It seems that the increase of G1/S phase population came mainly from S phase since the S phase decreased from 17.38% to 2.28% after treatment and no significant change was observed for G2 phase.
Identification of Antitumor Activities in TB-SN
We attempted to identify the active components in the TB-SN responsible for the growth inhibitory effect on A549 cells. The culture supernatant could contain macromolecules like proteins and polysaccharides as well as small organic molecules including amino acids, monosaccharide and nucleic acids, and inorganic molecules. Among them, proteins are heat-sensitive, while other components are heat-resistant. To determine if the active component of TB-SN is protein, we compared the growth inhibition effect of TB-SN with and without heat treatment at 100 o C for 10 minutes. Interestingly, TB-SN lost most of the activity after heating (Fig. 6) . Similar results were obtained when proteins were removed from TB-SN by TCA precipitation (Fig. 6) . These data indicated that proteins are the main component in TN-SN, which causes the growth inhibitory effect on A549 cells. To identify the molecule weight of the protein or protein complex responsible for the inhibitory effect of TB-SN, Amicon Ultra Centrifugal Separation System (Millipore) was used to fractionate TB-SN into several different molecular weights, including less than 3 kD, 3 ~ 10 kD, 10 ~ 100 kD and more than 100 kD. These fractions were further tested on A549 cells for growth inhibitory effect. As shown in Fig. (6) , the fractions with molecular weight more than 100 kD contained most of the activities of TB-SN. Taken together, these data indicated that the active component of TB-SN could be proteins or protein complex with molecular weight more than 100 kD.
DISCUSSION
It has remained controversial concerning the possible association between M. tuberculosis and lung cancer since the middle of 19th century. Some authors claim that tuberculosis promotes development of cancer [32] , while others assert that tuberculosis and cancer are antagonistic [33] . Therefore, it is difficult to assess the relationship of M. tuberculosis and lung cancer simply based on their coexistence. In this study, we demonstrated that TB-SN could cause significant growth inhibition in various human cancer cell lines including human lung cancer cell line A549 at low concentrations. The IC50 of TB-SN in A549 lung cancer cell is about 5 g/ml. LDH release assay revealed that TB-SN had cytotoxic effects on A549 lung cancer cells. At a concentration of 5 g/ml, TB-SN had about 29.2% of cytotoxicity of Triton X-100 (1%), a positive control that can cause almost all cell death through cytotoxic effect. In addition, we found that TB-SN could induce cell apoptosis. At a concentration of 5 g/ml, TB-SN could induce about 36.8% A549 cancer cells to undergo apoptosis as shown in the TUNEL apoptosis assay. Further studies revealed that this apoptosis was induced through an extrinsic caspase-dependent pathway, as TB-SN at 20 g/ml could increase caspase 3/7 and 8 levels by 6.61-and 4.72-fold, respectively, after treatment with TB-SN for 5 hours. Caspase 3 is a critical effector caspase in caspase-dependent apoptosis pathway [34] . When A549 cancer cells were pretreated with caspase 3 inhibitor DEVD-fmk, the apoptosis percentage decreased significantly. Since reduction in cell growth and induction in cell death are two major means to inhibit tumor growth [35] , TB-SN has good potential to be developed into useful treatment for human cancers.
cDNA microarray is a powerful tool to identify mechanism of action of drugs [36] . In this study, cDNA microarray demonstrated that TB-SN treatment dramatically changed the profile of gene expression in A549 lung cancer cells. Altogether, 196 functionally related genes were altered after 4 hour treatment and 371 genes after 5 day treatment. Among these, 2 genes were found to change more than 5-fold after 4 hour treatment, and 15 genes more than 10-fold after 5 day treatment with 7 genes down-regulated and 8 genes upregulated. The gene expression pattern of A549 cancer cells after TB-SN treatment indicated that TB-SN might work through several mechanisms. First, TB-SN may activate Gprotein coupled receptor signaling pathway, since OR10H3 was dramatically up-regulated over 132-fold after 5 day treatment. Also, NTS and CALM1 involved in signal transduction were induced over 10-fold. Second, TB-SN might regulate cell cycle since four genes including GSPT1, CCND1, STK6, UBE2V1 were down-regulated significantly over 10-fold. These data are consistent with the cell cycle analysis by flow cytometry, which demonstrated that TB-SN could induce A549 cancer cells arrest at G1/S checkpoint. Third, TB-SN may induce apoptosis, as expression of 13 apoptosis related genes was altered after TB-SN treatment. This result is consistent with the TUNEL staining result. All these results indicated that TB-SN could activate G-protein coupled signaling pathway and induce cell apoptosis and cell cycle arrest at G1/S checkpoint as potential mechanisms of action.
Chemical and physical analyses suggest that the active components in TB-SN responsible for inhibition of cell proliferation were protein or protein complexes with molecular weight greater than 100 kD. Further work is needed to identify the active components. Also, the gene expression profile of CCHCR1 gene in TB-SN treatment was remarkable, since it Growth Inhibition (% of control)
was down-regulated about 193-fold after 4 hours treatment and up-regulated over 200-fold after 5 day treatment. However its function is still unclear and further studies are needed to clarify its role in TB-SN induced anticancer activity.
